Business Wire

SWEEP

6.9.2022 09:54:37 CEST | Business Wire | Press release

Share
Former French Minister of Agriculture and Food Julien Denormandie Joins Sweep as Chief Impact Officer

Sweep, the leading carbon management and reduction platform, today announced it has expanded its leadership team with the recruitment of former French Minister of Agriculture and Food Julien Denormandie as Chief Impact Officer. He officially joined on September 5.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005500/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Julien Denormandie (Photo: Cheick Saidou)

Julien Denormandie said: "I am thrilled to start this new chapter at Sweep. Recent years, and especially the last few months, have shown us that the fight against climate change is the challenge of the century. It also reminded us of the need to develop concrete, applicable solutions that generate results. Sweep perfectly aligns with this virtuous approach by helping companies to measure and reduce their carbon emissions. In my new role as Chief Impact Officer, I want to use my experience, coupled with the market-leading tools that Sweep has created, to support businesses in their climate journey and become agents of positive change in the low carbon economy.”

Julien Denormandie will work alongside Sweep’s four co-founders to pursue the efforts that have already established the French start-up as one of the fastest-growing climate tech firms and a trusted partner to organisations around the world.

The challenges of reducing carbon emissions are both related to the massive amount of data that needs to be collected and evaluated, and to network issues due to the vast number of stakeholders involved. Julien will be in charge of strengthening Sweep’s network approach to carbon management to help maximise the impact of their climate action. His remit will also include growing the business, both in France and internationally, and further establishing Sweep’s position as a leading partner to organisations committed to a low-carbon future.

Rachel Delacour, CEO and co-founder of Sweep said, "The challenge of reversing the spiral of climate change is massive. Our ambition is to help organisations transition to a model that will thrive in a low carbon economy. Julien Denormandie's arrival is at the heart of this ambition. He joins at a time when Sweep is entering a new stage of its growth and I am delighted that we will continue to develop our platform and offer together. He has a unique ability to solve complex, multidimensional problems, which is the very essence of the challenges facing organisations when reducing carbon emissions today. This is in Sweep's DNA and Julien's too!”

Minister of Agriculture and Food from July 2020 to May 2022 in Jean Castex's government, Julien Denormandie was previously Deputy to the Minister of Territorial Cohesion in the government of Edouard Philippe between June 2017 and October 2018 and then Minister in charge of Cities and Housing until July 2020. He was successively advisor to the Minister in charge of Foreign Trade, Nicole Bricq, to the Minister of Economy and Finance, Pierre Moscovici before becoming Deputy Chief of Staff of the Minister of Economy, under Emmanuel Macron between 2012 and 2016. Ingénieur des ponts, des eaux et des forêts, he began his career on secondment to the Department of External Relations of the Ministry of the Economy before holding various positions at the French Embassy in Cairo and at the Treasury Department.

About Sweep

Sweep helps businesses track and act on their carbon so they can become forever companies.

The data-driven platform makes it easy to understand, manage and reduce your carbon footprint. Powerful collaboration features and user-focused design empower your staff and your entire value chain to grow a cleaner business. The platform also has an integrated marketplace, letting you contribute to exciting carbon reduction and removal projects around the world. And with all your data in one place, its analytics offer deep insights into your progress and automatic reporting to your stakeholders.

Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition and The International Emissions Trading Association. Visit sweep.net to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005500/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye